Molecular Psychiatry submission guide
Molecular Psychiatry's submission process, first-decision timing, and the editorial checks that matter before peer review begins.
Readiness scan
Before you submit to Molecular Psychiatry, pressure-test the manuscript.
Run the Free Readiness Scan to catch the issues most likely to stop the paper before peer review.
Key numbers before you submit to Molecular Psychiatry
Acceptance rate, editorial speed, and cost context — the metrics that shape whether and how you submit.
What acceptance rate actually means here
- Molecular Psychiatry accepts roughly ~12% of submissions — but desk rejection runs higher.
- Scope misfit and framing problems drive most early rejections, not weak methodology.
- Papers that reach peer review face a different bar: novelty, rigor, and fit with the journal's editorial identity.
What to check before you upload
- Scope fit — does your paper address the exact problem this journal publishes on?
- Desk decisions are fast; scope problems surface within days.
- Cover letter framing — editors use it to judge fit before reading the manuscript.
How to approach Molecular Psychiatry
Use the submission guide like a working checklist. The goal is to make fit, package completeness, and cover-letter framing obvious before you open the portal.
Stage | What to check |
|---|---|
1. Scope | Pre-submission inquiry (optional but recommended) |
2. Package | Initial manuscript submission |
3. Cover letter | Editorial triage and desk decision |
4. Final check | Peer review |
Quick answer: Molecular Psychiatry is a Springer Nature journal that is commonly estimated to accept about 10-15% of submissions. The journal is not looking for interesting neuroscience with a psychiatric label. Impact factor: 10.1 (per Clarivate JCR 2024, Q1 Psychiatry).
The editorial filter is whether the paper genuinely changes understanding of mental illness at the mechanistic or translational level, not whether it uses psychiatric vocabulary.
Run a Molecular Psychiatry pre-submission readiness check before you open the Springer Nature upload system, or use this guide to screen the package manually.
From our manuscript review practice
Of manuscripts we've reviewed for Molecular Psychiatry, neuroscience papers framed as psychiatric without clinical validation, or translational overclaiming where preclinical perturbation is presented as equivalent to medication efficacy or diagnostic utility, are desk-rejected. Human studies with inadequate medication dosing detail or diagnostic criteria precision fail psychiatric rigor standards.
What official pages do not answer
Official Nature Portfolio pages answer the formal questions: journal scope, online submission, article preparation, editorial policies, open-access costs, and median timing. That is necessary, but it still leaves the author with the hard pre-submit decision: whether the manuscript actually reads like Molecular Psychiatry on page one.
This guide separates translating the journal's biological-psychiatry scope into editorial screen logic. Official guidance does not tell you whether the title, abstract, first figure, cohort description, and cover letter make the psychiatric consequence visible quickly enough for a selective first read.
How this page was created: we checked Nature Portfolio's Molecular Psychiatry journal information, author and referee pages, preparation guidance, how-to-submit page, public journal metrics, and our Manusights review patterns from psychiatry-facing neuroscience manuscripts.
Source limitations: we did not test a private Molecular Psychiatry submission with a live manuscript in the portal. Portal labels and required fields can change, so use the official author instructions for final upload mechanics.
This guide tells you what Molecular Psychiatry editors look for before review. The review tells you whether your paper passes that first-read screen. Manusights has reviewed manuscripts targeting Molecular Psychiatry and nearby psychiatry journals, uses zero-retention manuscript processing, and we do not train models on your manuscript. Paid reports include a money-back guarantee on report delivery quality.
Molecular Psychiatry Submission Requirements
Method note: This Molecular Psychiatry submission guide was updated against Springer Nature's Molecular Psychiatry journal information page, preparation-of-articles instructions, how-to-submit page, journal metrics, and Manusights pre-submission review patterns for psychiatry-facing neuroscience manuscripts. Use this page for pre-upload package readiness; use the submission-process, impact-factor, review-time, or journal-profile pages for those separate intents.
Requirement | Standard |
|---|---|
Submission portal | |
Article types | Original Article, Brief Communication, Review |
Word limit | 4,000 words for original articles, excluding abstract and references |
Abstract | Single continuous paragraph, 150-250 words, no headings |
Figures and tables | No formal figure cap is stated in the public preparation guidance; keep displays necessary, readable, and aligned with the main claim |
First editorial decision | Median 32 days |
APC (open access) | ~$5,790 |
Editorial triage timeline after upload
Stage | Typical timing | What Molecular Psychiatry is checking |
|---|---|---|
Day 0 | Upload through Nature Portfolio journal page | Complete files, article type, cover letter, declarations, and figure/table package |
Days 1 to 7 | Administrative and editor screen | Whether the manuscript is genuinely psychiatry-facing rather than neuroscience with psychiatric vocabulary |
Days 7 to 14 | Deeper editorial triage | Whether the mechanism, cohort, confound handling, and translational claim are proportionate |
Weeks 2 to 5 | Reviewer routing if it passes triage | Whether the editor can identify reviewers across molecular, psychiatric, and translational domains |
Weeks 4 to 8+ | First decision window for reviewed papers | Whether reviewer comments point toward revision, transfer, or rejection |
- Day 0: Upload through Nature Portfolio journal page with main manuscript, figures, tables, supplementary information, and editor-facing note.
- Day 1 to 7: Administrative and editor screening checks completeness, declarations, article type, and psychiatric fit.
- Day 7 to 14: Editorial triage tests whether the mechanism, cohort, confounds, and translational claim are proportionate.
- Day 14 to 35: Reviewer routing starts if the manuscript clearly joins molecular depth with psychiatric consequence.
- Day 32 to 60: Reviewed papers typically move toward first decision, revision, transfer, or rejection depending on reviewer availability.
Required artifacts before Molecular Psychiatry upload
- Cover letter explaining why the manuscript belongs in Molecular Psychiatry rather than a broader neuroscience or clinical psychiatry journal.
- Data availability statement that matches Springer Nature policy and the actual sharing plan.
- Ethics approval statement for human, animal, or sensitive-data work where applicable.
- Conflicts of interest disclosure for all authors.
- Author contributions statement and funding statement.
- Supplementary material with cohort detail, analysis logic, sensitivity checks, and secondary figures where needed.
- ORCID details and suggested reviewers if the submission system requests them.
Submit If
- the paper genuinely moves psychiatric understanding forward: a mechanistic finding with clear relevance to a specific disorder, or a human psychiatric study with molecular or translational depth
- human studies: the cohort is adequately powered, medication effects and diagnostic heterogeneity are addressed directly, and the main finding would be actionable for psychiatric research or clinical practice
- preclinical studies: the translational argument connects to psychiatric pathology in a specific and testable way, not a speculative paragraph in the discussion
- the psychiatric consequence is visible from the abstract without requiring a specialist translation
Think Twice If
- the abstract names depression, schizophrenia, bipolar disorder, or anxiety, but the first figure still measures a general neural or molecular process with no psychiatric-relevant outcome
- translational claims in the discussion section significantly outrun what the medication, model, patient-sample, or biomarker evidence actually supports
- human cohort limitations are acknowledged only in the limitations paragraph rather than addressed in the methods, covariates, subgroup logic, or sensitivity analysis
- the cover letter would need to explain the psychiatric fit because the title, abstract, and first page do not make it obvious on their own
Quick answer: how to submit to Molecular Psychiatry
Molecular Psychiatry submission is usually straightforward in the portal and demanding at the level that matters: editorial fit. The journal is not looking for interesting neuroscience with a psychiatric label attached. It is looking for mechanistic work that genuinely changes how we understand mental illness, or clinical psychiatric research with serious molecular or translational depth.
The practical sequence is:
- decide whether the paper is truly psychiatry-facing rather than merely neuroscience-adjacent
- make the mechanistic and psychiatric consequence obvious early
- close sample, confound, and translational overclaim problems before submission
What this page is for
This page is about package readiness before upload.
Use it when you are still deciding:
- whether the manuscript is psychiatry-facing enough already
- whether the mechanistic and psychiatric claims are proportionate to the data
- whether the first page, first figures, and cover letter support the same fit argument
- whether the package is stable enough for a hard editorial screen
If you want to decide whether Molecular Psychiatry is the right journal at all, use the verdict page. If the file is already in the system and you are trying to interpret silence, triage, or review movement, use the submission-process page.
Before you open the submission portal
Before upload, ask the package these questions:
- Does the manuscript make a psychiatric point, not just a molecular biology point?
- Are the claimed mechanistic insights actually supported by the data?
- If this is human work, are medication, heterogeneity, and sample issues handled honestly?
- If this is preclinical work, is the translational argument proportionate rather than inflated?
- Can you explain why this belongs in Molecular Psychiatry instead of a broader neuroscience or a more purely clinical psychiatry journal?
The journal gets much easier when the answer to that last question is obvious from the title and abstract.
Peer-journal comparison before choosing Molecular Psychiatry
Fit question | Molecular Psychiatry | Translational Psychiatry | Biological Psychiatry |
|---|---|---|---|
Best fit | Mechanistic or translational work that directly changes understanding of psychiatric illness | Psychiatry-facing translational studies with a wider selectivity band and open-access route | Clinically and biologically important psychiatry research with strong field relevance |
Evidence bar | Molecular depth and psychiatric consequence must both be visible in the same package | Translational relevance can be broader if the psychiatric question is clear | Clinical, biological, and mechanistic credibility must support a field-level claim |
When to choose it | The title, abstract, first figure, methods, and cover letter all make the disorder-specific mechanism obvious | The study is rigorous and psychiatry-facing but may not clear the Molecular Psychiatry novelty bar | The manuscript's clinical psychiatry contribution is at least as strong as the molecular mechanism |
When to retarget | The work is interesting neuroscience with psychiatric framing added late | The work needs more selective editorial positioning or stronger molecular depth | The contribution is primarily molecular without enough clinical or disorder-level consequence |
1. Define the paper's real editorial identity
Molecular Psychiatry can handle different paper types, but the manuscript still needs to know what it is:
- a human psychiatric study with molecular depth
- a mechanistic paper with clear psychiatric relevance
- an integrative multi-level paper connecting genes, cells, circuits, and symptoms
- a translational piece where the psychiatric consequence is real, not decorative
Submissions get weaker when they sound psychiatric in the introduction and purely molecular in the actual data.
2. Assemble the package before login
Have the review-ready package built before entering the portal:
- main manuscript
- figures and tables in the right narrative order
- supplement with cohort detail, analysis logic, and secondary checks
- code or data availability details where relevant
- cover letter written specifically for Molecular Psychiatry
The journal is selective enough that anything which looks unfinished becomes part of the editorial signal.
3. Make the first page prove the psychiatric relevance
The editor should not have to infer why the study matters to psychiatry. The title, abstract, and first figure should already make that point.
The strongest packages usually show:
- what psychiatric question changed
- what mechanistic or translational insight was added
- why the paper is stronger than a correlation-only story
If the manuscript needs several pages to prove it belongs in psychiatry, the fit is weaker than authors think.
4. Expect an editorial screen focused on depth and relevance
At the first screen, editors are usually deciding:
- is the paper really about psychiatry
- are the mechanistic claims proportionate to the evidence
- are sample size, confounds, and analysis choices strong enough
- will review focus on significance rather than fundamental cleanup
This is where loose translational claims and under-argued psychiatric relevance tend to hurt.
5. Reviewer routing depends on conceptual clarity
Papers that clearly connect mechanism and disorder are easier to route. Papers that look partly molecular neuroscience, partly psychiatry framing, and partly exploratory association study create drag because the editor has to decide what the core contribution actually is. Editors invest time in finding reviewers who can evaluate the paper against the right standard.
When a submission does not have a stable editorial identity, that routing becomes uncertain, and mismatched reviewers generate feedback that misses the paper's real strengths. A clear editorial identity is not a stylistic preference; it determines whether the review conversation is productive.
Readiness check
Run the scan while Molecular Psychiatry's requirements are in front of you.
See how this manuscript scores against Molecular Psychiatry's requirements before you submit.
Common mistakes and avoidable delays
- Treating an association-heavy paper as if it already proves mechanism.
- Overstating the psychiatric relevance of rodent or cellular work.
- Ignoring medication, diagnosis, cohort heterogeneity, or other obvious human-study confounds.
- Claiming translational significance without enough evidence for that leap.
- Submitting a package that reads more like general neuroscience with psychiatric keywords added later.
- Using a cover letter that summarizes the manuscript but never explains why Molecular Psychiatry is the right journal.
- Letting the supplement carry key caveats the editor needed to see earlier.
What editors are actually screening for
Editorial criterion | What passes | Desk-rejection trigger |
|---|---|---|
Psychiatric relevance | The manuscript genuinely moves psychiatric understanding forward; the disorder is the primary subject of the work, not just a motivating context in the introduction | If the manuscript feels like molecular biology first and psychiatry second, the fit weakens immediately; editors are specifically looking for papers where removing the psychiatric framing would leave a shell |
Mechanistic discipline | The strongest claims are proportionate to the evidence; the paper does not overinterpret associations as mechanisms or project translational significance beyond what the data directly support | Ambitious interpretation that outruns the data is identified quickly by reviewers with deep domain knowledge; this journal is not a home for speculative leaps from association to causation |
Sample credibility and confounds | For human studies, cohort quality, medication handling, diagnostic definition, and confound awareness are addressed directly in the analysis rather than deferred to limitations | Loose handling of medication effects, heterogeneous diagnostic groups, or underpowered cohorts consistently triggers major revision requests before the science is even evaluated on its merits |
Multi-level integration | The manuscript links levels of evidence cleanly, connecting genetic, cellular, circuit, or systems data to a coherent psychiatric narrative | Papers that gesture at genes, circuits, and symptoms without integrating them convincingly leave the editor uncertain what the actual scientific contribution is |
What a strong cover letter does here
For Molecular Psychiatry, the cover letter should make the editorial case directly. It should not just restate the abstract.
A useful cover letter usually explains:
- what psychiatric problem or mechanism this paper clarifies
- why the data justify the level of claim being made
- why the work belongs in Molecular Psychiatry rather than a general neuroscience or clinical psychiatry title
- why the package is already mature enough for serious review
How to judge fit before you submit
Molecular Psychiatry is one of the easiest journals to misread. Authors often equate psychiatric keywords with fit. That is not enough.
The better fit questions are:
- does the manuscript say something consequential about mental illness rather than only about biology
- is the molecular or mechanistic component central instead of decorative
- will the paper still look persuasive after the translational language is stripped back to what the data really support
If those answers are weak, the journal fit is weak, no matter how interesting the underlying science is.
What a reviewer-ready Molecular Psychiatry package looks like
The strongest packages usually feel settled before submission:
- the title and abstract make the psychiatric consequence explicit
- the first figure shows more than an intriguing association
- cohort limitations and confounds are acknowledged before review
- translational claims are proportional to the evidence
- the supplement answers the obvious reviewer attacks on sample quality, confounds, and interpretation
That matters because the first editor screen is partly about trust. The package should signal that the authors already understand the hardest questions their reviewers will ask.
A practical pre-submit checklist
- the title and abstract make the psychiatric consequence clear
- the first figure supports the main mechanistic or translational point
- the strongest claim is proportionate to the evidence
- confounds are handled honestly and visibly
- the supplement answers foreseeable reviewer objections
- the cover letter argues for Molecular Psychiatry specifically
- the manuscript reads like one coherent paper rather than several half-connected frames
Molecular Psychiatry pre-submission checklist
- [ ] The abstract states the psychiatric disorder, mechanism, and consequence without relying on broad mental-health language.
- [ ] The first figure connects the biology to a psychiatric-relevant outcome, phenotype, cohort, or translational claim.
- [ ] Medication exposure, diagnostic heterogeneity, comorbidity, and sample-size limits are visible in the methods or analysis plan, not hidden in the discussion.
- [ ] The cover letter explains why Molecular Psychiatry is the right Nature Portfolio lane instead of Nature Neuroscience, Translational Psychiatry, Biological Psychiatry, or a specialist neuroscience journal.
- [ ] The strongest translational claim survives if every speculative sentence is removed from the discussion.
What usually weakens the package before review
The most common problem is a paper that is interesting but not yet settled enough for the journal's editorial bar.
That often looks like:
- translational language that outruns the actual evidence
- psychiatric framing that feels appended rather than central
- a human cohort story with confounds that are still too exposed
- preclinical work that implies clinical consequence without earning it
Those are exactly the problems editors are trying to identify before they commit reviewers.
What the editor needs to believe quickly
Before the paper gets out to review, the editor usually needs to believe:
- this is genuinely a Molecular Psychiatry paper, not just neuroscience with psychiatric keywords
- the mechanistic or translational claim is proportionate
- the major confound questions are already handled well enough for review to be productive
If the first read still feels unstable on those points, the submission becomes much harder to defend.
Bottom line before you submit
Molecular Psychiatry is the right target when the paper genuinely joins molecular or mechanistic depth with a credible psychiatric consequence.
If the manuscript still feels like interesting neuroscience searching for a psychiatric home, it is probably not ready for this journal.
The cleanest submissions usually make that decision easy for the editor. They do not ask the journal to rescue the fit argument after upload or after review begins. They already look like a Molecular Psychiatry manuscript from the first page.
Before you upload, run your manuscript through a Molecular Psychiatry submission readiness check to catch the issues editors filter for on first read.
Fast editorial screen table
If the manuscript looks like this on page one | Likely editorial read |
|---|---|
Psychiatric consequence, mechanistic depth, and reviewer-ready evidence are visible immediately | Stronger Molecular Psychiatry fit |
Biology is strong, but the psychiatric relevance still feels appended | Too weak for this journal |
Human or cohort framing exists, but confounds still look overly exposed | Harder editorial case |
Translational language is carrying more weight than the data package | Exposed at triage |
Decision risks before submitting to Molecular Psychiatry
For manuscripts targeting Molecular Psychiatry, three issues consistently trigger desk rejection among the papers we analyze.
Manusights pre-submission pattern analysis shows many desk rejections at Molecular Psychiatry trace to scope or framing problems that prevent the paper from competing in this venue. The same pattern analysis often finds these cases involve insufficient methodological rigor or missing validation evidence. A related pattern is that these cases often arise from a novelty claim that outpaces the supporting data.
Neuroscience papers with psychiatric framing rather than psychiatric content
Molecular Psychiatry's editorial guidelines specify that accepted papers must have "direct relevance to understanding human psychiatric illness." The failure pattern is a paper that is structurally a molecular neuroscience study where the psychiatric relevance is established only by citing epidemiological evidence of the target's association with schizophrenia or depression in the introduction and discussion.
Editors return these with the consistent note that the psychiatric connection is established by prior literature rather than demonstrated by the submitted work. SciRev author-reported data confirms Molecular Psychiatry's median first decision at approximately 4-6 weeks, with desk rejections typically at the 2-3 week mark.
Check if your psychiatric fit is visible on page one →
Translational overclaiming from preclinical or cellular data
Molecular Psychiatry reviewers consistently flag manuscripts where the discussion section concludes that preclinical findings "suggest therapeutic implications" or "open new avenues for drug development" without specifying a mechanism, target, or feasibility argument. The failure pattern is a rodent study showing behavioral rescue after genetic or pharmacological manipulation, where the Discussion section pivots to clinical implications without acknowledging the translational gap. Editors are particularly critical of this pattern when the animal model used is not well validated for the specific disorder claimed.
Check whether your translational claim is proportionate →
Verify format requirements against the journal's author guidelines before uploading.
Inadequate handling of medication effects and diagnostic heterogeneity in human studies
For human psychiatric research, Molecular Psychiatry reviewers expect explicit analysis of medication effects on the primary outcome measure, particularly in studies involving psychiatric patients compared to healthy controls. The failure pattern is a study reporting differences between a patient group and controls where a substantial fraction of patients are taking antipsychotics, antidepressants, or mood stabilizers, and the analysis treats the groups as homogeneous without addressing medication as a covariate.
We find this is one of the most consistent major revision triggers at Molecular Psychiatry for human neuroimaging and biomarker studies. A Molecular Psychiatry submission readiness check can identify translational framing and confound handling issues before the submission window.
Check your medication and cohort-confound handling →
Editors consistently screen submissions against these patterns before sending to peer review, so addressing them before upload improves the chance that review starts on the right scientific question.
Related submission guides
Use these nearby guides when the target journal is still uncertain:
What to verify against official guidance
Use official guidance for live requirements. For Molecular Psychiatry submission guide, the Manusights decision layer focuses on the manuscript-level fit, evidence, routing, and first-screen questions that public author instructions usually cannot answer for an individual draft.
Related next steps
Evidence basis
The Manusights editorial review for Molecular Psychiatry submission guide combines official guidance, adjacent Manusights cluster pages, and first-party pre-submission review patterns. They are used here to clarify manuscript-readiness decisions, not to replace publisher instructions.
Useful next pages
These pages cover desk rejection patterns, submission process expectations, journal quality assessment, and comparison with nearby high-impact neuroscience and psychiatry journals.
- How to Avoid Desk Rejection at Molecular Psychiatry
- Molecular Psychiatry submission process
- Is Molecular Psychiatry a Good Journal?
How this Molecular Psychiatry guide was checked
For the related journal overview, see Molecular Psychiatry journal guide. In our work on Molecular Psychiatry submissions, we observe that editors specifically screen the abstract, first figures, cover letter, and evidence package for whether the manuscript answers the journal's stated fit test; our analysis of Molecular Psychiatry pages treats those checks as submission-risk signals, not as official guidance.
Frequently asked questions
Molecular Psychiatry uses an online submission portal through Springer Nature. Prepare your manuscript ensuring it is truly psychiatry-facing rather than merely neuroscience-adjacent, make the mechanistic and psychiatric consequence obvious early, and close sample, confound, and translational overclaim problems before submission. Upload the manuscript package with a cover letter explaining why the paper belongs in this journal.
The public journal information reports a median first editorial decision of about 32 days. Desk-screen decisions can be faster, while manuscripts sent to external review depend on reviewer availability and revision depth.
Check the Springer Nature preparation guidance before upload. The package should include the main manuscript, abstract, figures and tables, supplementary information, data availability statement, ethics approval details where relevant, conflicts of interest, funding statement, author contributions, ORCID details, and suggested reviewers if requested.
Common rejection reasons include framing neuroscience work as psychiatry without genuine psychiatric relevance, overstating translational implications of preclinical data, inadequate handling of medication effects, sample heterogeneity, or confounding variables in human studies, and submitting papers better suited to a broader neuroscience or purely clinical psychiatry journal.
Molecular Psychiatry is a hybrid Springer Nature journal. Subscription publication may carry no author charge, while optional open access uses Springer Nature APC pricing and institutional agreement rules, so authors should verify the current cost and waiver status before choosing OA.
Sources
- 1. Molecular Psychiatry journal homepage, Springer Nature.
- 2. Molecular Psychiatry journal information, Springer Nature.
- 3. Molecular Psychiatry preparation of articles, Springer Nature.
- 4. Molecular Psychiatry how to submit, Springer Nature.
- 5. Molecular Psychiatry editorial policies, Springer Nature.
- 6. Nature Portfolio editorial policies, Springer Nature.
- 7. Springer Nature APC waivers and discounts, Springer Nature.
- 8. Clarivate Journal Citation Reports (JCR 2024), Clarivate Analytics.
Final step
Submitting to Molecular Psychiatry?
Run the Free Readiness Scan to see score, top issues, and journal-fit signals before you submit.
Target journal carried over: Molecular Psychiatry
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Start here
Same journal, next question
- How to Avoid Desk Rejection at Molecular Psychiatry
- Molecular Psychiatry submission process
- Molecular Psychiatry Review Time: What Authors Can Actually Expect
- Molecular Psychiatry Under Review: What the Status Means
- Molecular Psychiatry Impact Factor 2026: 10.1, Q1, Rank 7/288
- Is Molecular Psychiatry a Good Journal? Impact Factor, Scope, and Fit Guide